Stock Market & Financial Investment News

News For LLY;PFE From The Last 14 Days Check below for free stories on LLY;PFE the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 08:59 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 08:06 EDT PFE Zoetis comments on Pfizer’s split-off plans for remaining interest Subscribe for More Information 08:04 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information 08:02 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information May 21, 2013 07:24 EDT LLY Global Health Care to host a conference Subscribe for More Information 07:16 EDT PFE Pfizer management to meet with Leerink Subscribe for More Information May 20, 2013 17:04 EDT PFE Pfizer discontinues phase 3 study of inotuzumab ozogamicin Subscribe for More Information May 16, 2013 08:55 EDT LLY, PFE BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information May 14, 2013 09:09 EDT LLY Eli Lilly announces CEO John Lechleiter recovering from surgery Subscribe for More Information 07:24 EDT LLY EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 10, 2013 16:29 EDT PFE On The Fly: Closing Wrap Subscribe for More Information 12:31 EDT PFE On The Fly: Midday Wrap Subscribe for More Information 11:48 EDT PFE, LLY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 09:21 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 08:08 EDT PFE Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence. 08:02 EDT LLY Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. 07:46 EDT PFE DURECT says additional clinical studies needed for Remoxy DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39. May 9, 2013 11:01 EDT LLY Sears Holdings names Jeff Balagna Chief Information Officer Subscribe for More Information 10:17 EDT PFE Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.